KR900004937A - RNA catalyst to segment unusual RNA sequence - Google Patents

RNA catalyst to segment unusual RNA sequence Download PDF

Info

Publication number
KR900004937A
KR900004937A KR1019890013596A KR890013596A KR900004937A KR 900004937 A KR900004937 A KR 900004937A KR 1019890013596 A KR1019890013596 A KR 1019890013596A KR 890013596 A KR890013596 A KR 890013596A KR 900004937 A KR900004937 A KR 900004937A
Authority
KR
South Korea
Prior art keywords
rna
catalyst
sequence
substrate
bases
Prior art date
Application number
KR1019890013596A
Other languages
Korean (ko)
Inventor
이.함펠 아놀드
에이치.트리츠 리차드
에프.힉스 마가렛
Original Assignee
노썬 일리노이스 유니버시티
바이오테크노로지 리써치 앤드 데벨로프먼트 코포레이숀 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22933553&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900004937(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노썬 일리노이스 유니버시티, 바이오테크노로지 리써치 앤드 데벨로프먼트 코포레이숀 인코포레이티드 filed Critical 노썬 일리노이스 유니버시티
Publication of KR900004937A publication Critical patent/KR900004937A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Abstract

A synthetic RNA catalyst capable of cleaving an RNA substrate, the catalyst comprising a substrate binding portion and a "hairpin" portion. The invention also provides an engineered DNA molecule and a vector, each comprising a DNA sequence coding for an RNA catalyst according to the invention. The invention further comprises host cells transformed with the vectors of the invention which are capable of expressing the RNA substrate. Finally, the invention provides a method of cleaving an RNA substrate which comprises contacting the substrate with a synthetic RNA catalyst according to the invention. <IMAGE>

Description

특이한 RNA 배열순서를 분할하는 RNA촉매RNA catalysts that cleave specific RNA sequences

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 본 발명에 따른 촉매 RNA의 “머리핀"모델에 맞는 (-)sTRSV RNA 기질촉매 복합체를 나타낸다.Figure 1 shows a (-) sTRSV RNA substrate catalyst complex that fits the "hairpin" model of catalytic RNA according to the present invention.

제2도는 (-)sTRSV RNA의 최소 애너지 주름을 나타낸다.2 shows the minimal energy wrinkle of (-) sTRSV RNA.

제3도는 촉매 RNA에 의한 기질 RNA의 촉매작용의 시간 경로를 나타낸다.3 shows the time course of catalysis of substrate RNA by catalytic RNA.

Claims (43)

다음의 배열순서를 포함하는 RNA기질을 분할할 수 있는 합성 RNA 촉매:Synthetic RNA catalyst capable of partitioning RNA substrates comprising the following sequence: 5'-F1-CS-F2-3'5'-F 1 -CS-F 2 -3 ' 이식에서, CS는 분할 배열순서이고; 그리고 F1과 F2는 각각 분할 배열순서에 접하는 배열순서이고; 이촉매는 기질 결합부위와 “머리핀"부위를 포함하고 이 촉매의 기질결합 부위는 다음의 배열순서를 가지고:In transplantation, CS is in split array order; And F 1 and F 2 are each in direct contact with the divided array order; This catalyst comprises a substrate binding site and a “hairpin” site and the substrate binding site of the catalyst has the following sequence: 3'-F4-L1-F3-5'3'-F 4 -L 1 -F 3 -5 ' 이식에서, F3은 촉매가 기질에 결합될 때 F3과 F2와 실질적으로 염기쌍을 이루도록 선택된 염기의 배열 순서이고; F4는 이 촉매가 기질에 결합될 때 F4가 F1과 실질적으로 염기쌍을 이루도록 선택된 염기의 배열순서이고; F3와 F4의 배열순서는 이들 각각이 기질의 분할이 일어날 수 있도록 RNA 촉매에의 RNA기질의 충분한 결합을 얻도록 절절한 수의 염기를 포함하도록 선택되고; 그리고 L1은 이 촉매가 기질에 결합될 때 L1이 CS와 염기쌍을 이루지 않도록 선택된 염기이다.In implantation, F 3 is an order of sequence of bases selected to substantially base pair with F 3 and F 2 when the catalyst is bound to a substrate; F 4 is a catalyst that, when combined in the matrix F 4 F 1 and substantially fulfill the base pairs, and the arrangement order of the selected base; The sequence of F3 and F4 is selected such that each of them contains an appropriate number of bases to obtain sufficient binding of the RNA substrate to the RNA catalyst so that cleavage of the substrate can occur; And L 1 is a base selected such that L 1 does not base pair with CS when this catalyst is bound to a substrate. 제1항에 있어서, 촉매의 머리핀 부위가 다음의 배열순서를 가지는 RNA촉매:The RNA catalyst of claim 1, wherein the hairpin region of the catalyst has the following sequence: 이식에서, P1는 각각 염기의 배열손서이고 P1과 P4의 배열순서는 P1과 P4가 실질적으로 염기쌍을 이루도록 선택되고; P1은 F4에 공유결합되고;In transplantation, P 1 is arranged sonseo and arrangement order of P 1 and P 4 of the respective bases are the P 1 and P 4 is selected to achieve substantially the base pair; P 1 is covalently bound to F 4 ; S1과 S2는 각각 염기의 배열순서이고, S1과 S2의 배열순서는 S1과 S2가 실질적으로 쌍을 이루지 않도록 선택되고; P2와 P3는 각각 염기의 배열순서이고, P2와 P3의 배열순서는 P2와 P3가 실질적으로 염기쌍을 이루도록 선택되고; 그리고 L2는 쌍을 이루지 않는 염기의 배열순서이다.S 1 and S 2 is the arrangement order of the respective base, the arrangement order of S 1 and S 2 is S 1 and S 2 are selected so as to accomplish substantially the pair; P 2 and P 3 is the arrangement order of the respective base, the arrangement order of the P 2 and P 3 is the P 2 and P 3 substantially is selected to fulfill the base pair; And L 2 is a sequence of unpaired bases. 제1항 또는 제2항에 있어서, CS가 배열순서 5'-NGUS-35" 가지는 경우의 RNA기질을 분할할수 있고 N는 어떤 염기이고 기질은 N와 G사이에서 촉매에 의해서 분할되는 RNA촉매.The RNA catalyst according to claim 1 or 2, wherein the RNA substrate can be cleaved when CS has the sequence 5'-NGUS-35 ", where N is any base and the substrate is cleaved by a catalyst between N and G. 제3항에 있어서, L1이 배열순서 3'-AAGA-5'를 가지는 RNA촉매.The RNA catalyst of claim 3, wherein L 1 has the sequence 3′-AAGA-5 ′. 제1항 또는 제2항에 있어서, F3는 최소한 3염기이고, F4는 3 내지 5염기의 길이로 되고, 이 촉매기 F1과 F2가 각각 최소한 3염기의 길이인때에 기질을 분할하는 RNA촉매.3. The substrate of claim 1, wherein F 3 is at least 3 bases, F 4 is 3 to 5 bases in length, and the catalyst groups F 1 and F 2 are each at least 3 bases in length. Dividing RNA Catalyst. 제5항에 있어서, F3가 6 내지 12의 염기의 길이이고, F4가 4염기의 깅이이고, F1이 4염기의 길이이고 F2가 6 내지 12염기의 길이일 때 촉매가 기질을 분할하는 RNA촉매.The catalyst of claim 5 wherein F 3 is a length of 6 to 12 bases, F 4 is a gingham of 4 bases, F 1 is a length of 4 bases and F 2 is a length of 6 to 12 bases. RNA catalyst to divide. 제2항에 있어서, P1과 P4가 각각 3 내지 6염기의 길이인 RNA촉매.The RNA catalyst of claim 2, wherein P 1 and P 4 are each 3 to 6 bases in length. 제7항에 있어서, P1이 배열순서 5'-ACCAG-3'를 가지고 P가 배열순서 5'-CUGGUA-3' 배열순서를 가지는 RNA촉매.The RNA catalyst according to claim 7, wherein P 1 has the sequence 5′-ACCAG-3 ′ and P has the sequence 5′-CUGGUA-3 ′. 제2항에 있어서, S1과 S2가 각각 4 내지 7염기의 길이인 RNA촉매.The RNA catalyst of claim 2, wherein S 1 and S 2 are each 4 to 7 bases in length. 제9항에 있어서, S1이 배열순서 5'-AUAUUAC-3'을 가지고 S가 배열순서 5'-AUAUUAC-3'을 가지는 RNA촉매.The RNA catalyst according to claim 9, wherein S 1 has the sequence 5'-AUAUUAC-3 'and S has the sequence 5'-AUAUUAC-3'. 제2항에 있어서, P2와 P3가 각각 3 내지 6염기의 길이인 RNA촉매.The RNA catalyst of claim 2, wherein P 2 and P 3 are each 3 to 6 bases in length. 제11항에 있어서, P2가 배열순서 5'-ACACAC-3'를 가지고 P3가 배열순서 5'-GUGGU-3'을 가지는 RNA촉매.12. The RNA catalyst of claim 11, wherein P 2 has the sequence 5'-ACACAC-3 'and P3 has the sequence 5'-GUGGU-3'. 제2항에 있어서, L2가 최소한 3염기의 길이인 RNA촉매.The RNA catalyst of claim 2, wherein L 2 is at least three bases in length. 제13항에 있어서, L가 배열순서 5'-GUU-3'을 가지는 RNA촉매.The RNA catalyst according to claim 13, wherein L has a 5'-GUU-3 'sequence. 제2항에 있어서, 5'-S1-P2-L2가 배열순서 5'-AGAACACACGUU-3'을 가지는 RNA촉매.The RNA catalyst according to claim 2, wherein 5'-S 1 -P 2 -L 2 has the sequence 5'-AGAACACACGUU-3 '. 제1항 또는 제2항에 있어서, 전령 RNA, 운반 RNA, 리보소옴 RNA, 비루스 RNA, 핵 RNA, 기능질 RNA 및 기타 세포의 RNA으로 구성된 그룹에서 선택된 RNA기질을 분할할수 있는 RNA 촉매.The RNA catalyst of claim 1 or 2, wherein the RNA substrate is capable of cleaving an RNA substrate selected from the group consisting of messenger RNA, carrier RNA, ribosomal RNA, viral RNA, nuclear RNA, functional RNA, and other cellular RNA. 제16항에 있어서, HIV-1비루스 RNA와 담배 모자이크 비루스 RNA로된 그룹에서 선택된 RNA기질을 분할할 수 있는 촉매.The catalyst of claim 16, wherein the RNA substrate is selected from the group consisting of HIV-1 virus RNA and tobacco mosaic virus RNA. 제16항에 있어서, 클로르 암페니콜아세틸 전이효소를 코딩하는 전령 RNA를 분할할 수 있는 RNA촉매.The RNA catalyst according to claim 16, wherein the messenger RNA encoding chlor amphenicolacetyl transferase is cleavable. 제2항에 있어서, 다음의 배열순서를 포함하는 RNA 촉매:The RNA catalyst of claim 2 comprising the following sequence: 이식에서, F1, F2, F3, F4, L1, L2, S1, S2, P1, P2, P3및 P4는 제1항 및 제2항에서 정의된 것과 같고; 그리고 L3은 분자의 촉매부위를 기질부위와 공유결합시켜 합성의 자가촉매 반응식 RNA촉매를 생성하는 쌍을 이루지 않는 염기의 배열순서이다.In transplantation, F 1 , F 2 , F 3 , F 4 , L 1 , L 2 , S 1 , S 2 , P 1 , P 2 , P 3 and P 4 are as defined in claims 1 and 2 Equal to; L 3 is a sequence of unpaired bases that covalently bonds the catalytic site of the molecule with the substrate site to produce a synthetic autocatalytic RNA catalyst. 제19항에 있어서, CS가 배열순서 5'-NGUC-3'를 가지고 N는 어떤 염기이고 기질은 N와 G사이에서 촉매에 의해서 분할되는 RNA촉매.20. The RNA catalyst of claim 19, wherein CS has the sequence 5'-NGUC-3 'wherein N is any base and the substrate is cleaved by a catalyst between N and G. 제20항에 있어서, L1이 배열순서 3'-AAGA-5'를 가지는 RNA촉매.The RNA catalyst of claim 20, wherein L 1 has the sequence 3′-AAGA-5 ′. 제21항에 있어서, 5'-P1-S1-P2-L2-P3-S2-P4-3'이 배열순서 5'-ACCAGAGAAACACACGUUGUGGUAUAUUA-CCUGGUA-3'를 가지는 RNA 촉매.22. The method of claim 21, 5'-P 1 -S 1 -P 2 -L 2 -P 3 -S 2 -P 4 -3 ' The arrangement sequence 5'-ACCAGAGAAACACACGUUGUGGUAUAUUA-CCUGGUA-3' with the RNA catalyst. 제22항에 있어서, L3이 배열순서 3'-CCUCC-5'를 가지는 RNA촉매.The RNA catalyst of claim 22, wherein L 3 has the sequence 3′-CCUCC-5 ′. 다음의 배열순서와 이들의 활성종을 포함하는 RNA촉매: 5'-F3-L1-F4-ACCAGAGAAACACACGUUGUGGUAUAUUACCUGGUA-3'이식에서, CS는 분할배열순서이고; F1과 F2는 각각 분할배열순서에 접하는 염기의 배열순서이고; F3은 촉매가 기질에 결합될 때 F3이 F2와 실질적으로 염기쌍을 이룰 수 있도록 선택된 염기의 배열순서이고; F4는 촉매가 기질에 결합될 때 F4가 F1가 실질적으로 염기쌍을 이루도록 선택된 염기의 배열순서이고; F3과 F4의 배열순서는 기질의 분할이 일어날 수 있도록 RNA촉매에의 RNA기질의 충분한 결합을 얻도록 가각 적절한 수의 염기를 포함하도록 선택되고; 그리고 L1은 촉매가 기질에 결합될 때 L1이 CS가 염기쌍을 이루지 않도록 선택된 염기의 배열순서이다.RNA catalyst comprising the following sequence and their active species: 5'-F 3 -L 1 -F 4 -ACCAGAGAAACACACGUUGUGGUAUAUUACCUGGUA-3 'In the transplant, CS is the split sequence; F 1 and F 2 are each a sequence of bases in contact with a split sequence; F 3 is a sequence of bases selected such that when the catalyst is bound to the substrate, F 3 is substantially base-paired with F 2 ; F 4 is when the catalyst is bound to the matrix F 4 F 1 is substantially fulfill the base pair arrangement and order of the selected base; The sequence of F 3 and F 4 is chosen to include each appropriate number of bases to obtain sufficient binding of the RNA substrate to the RNA catalyst such that cleavage of the substrate occurs; And L 1 is a sequence of bases selected so that L 1 does not form a base pair when the catalyst is bound to a substrate. 24항에 있어서, F3이 최소한 3염기의 길이이고, F4는 3 내지 5염기의 길이이고, 촉매가 F1과 F2가 각각 최소한 3염기의 길이일 때 기질을 분할시키는 RNA 촉매.The RNA catalyst of claim 24, wherein F 3 is at least 3 bases in length, F 4 is 3 to 5 bases in length, and the catalyst splits the substrate when F 1 and F 2 are each at least 3 bases in length. 제25항에 있어서, F3이 6 내지 12염기의 길이이고, F4가 4 염기의 길이이고, 촉매가 F1이 4염기의 길이이고, F2가 6 내지 12염기의 길이일 때 기질을 분할시키는 RNA 촉매.The substrate of claim 25, wherein F 3 is 6-12 bases in length, F 4 is 4 bases in length, the catalyst is F 1 is 4 bases in length, and F 2 is 6-12 bases in length. Dividing RNA Catalyst. 제24항에 있어서, CS가 배열순서 5'-NGUC-3'를 가지는 RNA기질을 분할시킬 수 있고 N가 어떤염기이고 기질이 N와 G사이에서 촉매에 의해서 분할되는 RNA촉매.The RNA catalyst of claim 24, wherein CS is capable of cleaving RNA substrates having the sequence 5′-NGUC-3 ′ and wherein N is any base and the substrate is cleaved by a catalyst between N and G. 25. 제27항에 있어서, L1이 배열순서 3'-AAGA-5'를 가지는 RNA 촉매.The RNA catalyst of claim 27, wherein L 1 has the sequence 3′-AAGA-5 ′. 제24항에 있어서, 전령 RNA, 운반 RNA, 리보소음 RNA, 비루스성 RNA, 핵 RNA, 기능질 RNA 및 기타 세포의 RNA로 구성된 그룹에서 선택된 RNA기질을 분할시킬 수 있는 RNA 촉매.The RNA catalyst of claim 24, wherein the RNA substrate is capable of cleaving an RNA substrate selected from the group consisting of messenger RNA, carrier RNA, ribosomal RNA, viral virus, nuclear RNA, functional RNA, and other cell RNA. 제29항에 있어서, HIV-1비루스 RNA 및 담배 모자이크 비루스 RNA로된 그룹에서 선택된 RNA 기질을 분할시킬 수 있는 RNA촉매.The RNA catalyst of claim 29, wherein the RNA substrate is capable of cleaving an RNA substrate selected from the group consisting of HIV-1 virus RNA and tobacco mosaic virus RNA. 제29항에 있어서, 클로르 암페니콜아세틸 전이효소를 코딩하는 전령 RNA를 분할할 수 있는 RNA 촉매.The RNA catalyst according to claim 29, wherein the messenger RNA encoding chlor amphenicolacetyl transferase can be cleaved. 제1,2,19 또는 24항에 따른 RNA 촉매를 코딩하는 조작된 DNA 분자.An engineered DNA molecule encoding an RNA catalyst according to claim 1, 2, 19 or 24. 제1,2,19 또는 24항에 따른 RNA 촉매를 코딩하는 DNA배열순서를 포함하고, DNA 배열순서가 발현 기준 배열순서에 조작식으로 결합된 전달매개체(Vector).A delivery medium (Vector) comprising a DNA sequence encoding an RNA catalyst according to claim 1, 2, 19 or 24, wherein the DNA sequence is operably linked to the expression reference sequence. 제33항에 있어서, 숙주에서 자기-복제할 수 있는 전달매개체.The delivery medium of claim 33, which is self-replicating in the host. 제33항에 있어서, 전달매개체에 의해서 인코드된 RNA 촉매가 전령RNA, 운반RNA, 리보소옴RNA, 비루스RNA, 핵 RNA, 기능질 RNA 및 기타 세포의 RNA로 구성된 그룹에서 선택된 RNA배열순서를 분할할 수 있는 전달매개체.34. The RNA sequence of claim 33, wherein the RNA catalyst encoded by the delivery medium is capable of dividing an RNA sequence selected from the group consisting of messenger RNA, carrier RNA, ribosomal RNA, viral RNA, nuclear RNA, functional RNA and other cellular RNA. Transfer media. 제35항에 있어서, 전달매개체에 의해서 인코드된 RNA촉매가 HIV-1비루스 RNA 및 담배 모자이크 비루스 RNA로된 그룹에서 선택된 RNA기질을 분할할 수 있는 전달매개체.36. The delivery medium of claim 35, wherein the RNA catalyst encoded by the delivery medium is capable of cleaving an RNA substrate selected from the group consisting of HIV-1 virus RNA and tobacco mosaic virus RNA. 제35항에 있어서, 전달매개체에 의해서 인코드된 RNA촉매가 클로르 암페니콜아세틸 전이효소를 코딩하는 전령 RNA를 분할할 수 있는 전달매개체.36. The delivery medium of claim 35, wherein the RNA catalyst encoded by the delivery medium is capable of cleaving a messenger RNA encoding chlor amphenicolacetyl transferase. 제33,34,35,36 또는 37항에 따르고 RNA가 기질을 발현 할 수 있는 전달매개체로 형질전환된 숙주세포.A host cell according to claim 33, 34, 35, 36 or 37, wherein the RNA is transformed with a delivery medium capable of expressing a substrate. 다음 배열순서를 포함하는 RNA기질의 분할 방법에 있어서:In a method of dividing an RNA substrate comprising the following sequence: 5'-F1-CS-F2-3'5'-F 1 -CS-F 2 -3 ' 이식에서 CS가 분할 배열순서이고; 그리고 F1과 F2가 각각 분할배열순서에 접하는 염기의 배열순서이고; 이 방법이 기질결합부위와 “머리핀"부위를 포함하는 합성 RNA촉매를 기질과 접촉시키는 것을 포함하고, 촉매의 기질 결합부위는 다음의 배열순서를 가지는 RNA기질의 분할방법:CS is the partitioning sequence in the transplant; And F 1 and F 2 are the sequence of bases adjacent to the split sequence, respectively; This method involves contacting the substrate with a synthetic RNA catalyst comprising a substrate binding site and a “hairpin” site, wherein the substrate binding site of the catalyst comprises an RNA substrate having the following sequence: 3'-F4-L1-F3-5'3'-F 4 -L 1 -F 3 -5 ' 이식에서, F3은 촉매가 기질에 결합할 때 F3가 F2와 실질적으로 염기쌍을 이루도록 선택된 염기의 배열 순서이고; F4는 촉매가 기질에 결합할 때 F4가 F1과 실질적으로 염기쌍을 이루도록 선택된 염기의 배열순서이고; F3과 F4의 배열순서는 기질의 분할이 일어날 수 있도록 각각이 RNA 촉매에의 RNA기질의 충분한 결합을 얻을 수 있도록 적합한 수의 염기를 포함하도록 선택되고; 그리고 L1은 촉매가 기질에 결합할때 L1이 CS와 염기쌍을 이루지 않도록 선택된 염기의 배열순서이다.In implantation, F 3 is an order of sequence of bases selected such that F 3 is substantially base-paired with F 2 when the catalyst binds to the substrate; F 4 is a sequence of bases selected such that when the catalyst binds to the substrate, F 4 is substantially base-paired with F 1 ; The sequence of F 3 and F 4 is chosen to include a suitable number of bases so that each can obtain sufficient binding of the RNA substrate to the RNA catalyst so that substrate cleavage can occur; And L 1 is a sequence of bases selected so that L 1 does not base pair with CS when the catalyst binds to the substrate. 제39항에 있어서, 촉매의 머리핀 부위가 다음의 배열순서를 가지고:40. The hairpin portion of the catalyst according to claim 39, wherein the hairpin portion of the catalyst has the following sequence: P1과 P4는 각각 염기의 배열순서이고, P1과 P4의 배열순서는 P1과 P4가 실질적으로 쌍을 이루도록 선택되고; P1는 F4에 공유결합되고; S1과 S2는 각각 염기의 배열순서이고 S1과 S2의 배열 순서는 S1과 S2가 실질적으로 쌍을 이루지 않도록 선택되고; P2와 P3는 각각 염기의 배열순서이고 P2와 P3의 배열순서는 P2와 P3가 실질적으로 쌍을 이루도록 선택되고; 그리고 L2는 쌍이 아닌 염기의 배열순서이다.P 1 and P 4 is an arrangement order of the respective base, the arrangement order of P 1 and P 4 is the P 1 and P 4 is selected to achieve substantially the pair; P 1 is covalently bound to F 4 ; S 1 and S 2 is the arrangement order and arrangement order of S 1 and S 2 of the respective base is selected so that S 1 and S 2 fulfill the substantially pairs; P 2 and P 3 is the arrangement order and arrangement order of P 2 and P 3 of the respective base is the P 2 and P 3 substantially is selected to fulfill the pair; And L 2 is a sequence of bases, not pairs. 다음의 배열순서를 포함하는 합성 RNA촉매를 기질과 접촉시키는 것을 포함하는 배열순서 5'-F1-CS-F2-3'을 포함하는 RNA기질과 이들의 활성변종의 분할방법: 5'-F 3-L 1-F 4-ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA-3'이들식에서, CS는 분할 배열순서이고: F1과 F2는 분할 배열순서와 접하는 염기의 배열 순서이고; F3는 촉매가 기질과 결합될때 F3이 F2와 실질적인 염기쌍을 이루도록 선택된 염기의 배열순서이고; F4는 촉매가 기질에 결합될때 F4가 F1과 실질적으로 염기쌍을 이루도록 선택된 염기의 배열순서이고; F3과 F4의 배열순서는 기질의 분할이 일어나도록 RNA 촉매에의 RNA 기질의 충분한 결합을 얻는 적절한 수의 염기를 각각 포함하도록 선택되고; 그리고 L1은 촉매가 기질과 결합할때 L1이 CS와 염기쌍을 이루지 않도록 선택된 염기의 배열순서이다.RNA substrates comprising the sequence 5'-F 1 -CS-F 2 -3 'comprising contacting a synthetic RNA catalyst comprising the following sequence with a substrate: 5'- F 3-L 1-F 4-ACCAGAGAAACACACGUUGUGGUACAUUACCUGGUA-3 'In these formulas, CS is the split sequence: F 1 and F 2 are the sequences of bases adjacent to the split sequence; F 3 is the sequence of bases selected such that when the catalyst is bound to the substrate, F 3 is substantially a base pair with F 2 ; F 4 is a sequence of bases selected such that when the catalyst is bound to the substrate, F 4 is substantially base-paired with F 1 ; The sequence of F 3 and F 4 is selected to each include an appropriate number of bases to obtain sufficient binding of the RNA substrate to the RNA catalyst such that cleavage of the substrate occurs; And L 1 is a sequence of bases selected such that L 1 does not base pair with CS when the catalyst binds to the substrate. 제39,40 또는 40항에 있어서, 분할이 생리학 조건에서 일어나는 방법.The method of claim 39, 40 or 40, wherein the splitting occurs under physiological conditions. 제42항에 있어서, 분할이 RNA촉매를 코딩하는 DNA배열순서를 포함하는 전달매개체를 형질전환된 숙주세포에서 생체내에서 일어나고 DNA 배열순서는 발현 기존 배열순서에 조작식으로 결합된 방법.The method of claim 42, wherein the cleavage occurs in vivo in the host cell transformed with a delivery medium comprising a DNA sequence encoding an RNA catalyst and the DNA sequence is operably linked to an existing sequence of expression. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임※ Note: The disclosure is based on the initial application.
KR1019890013596A 1988-09-20 1989-09-20 RNA catalyst to segment unusual RNA sequence KR900004937A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24710088A 1988-09-20 1988-09-20
US7/247,100 1988-09-20

Publications (1)

Publication Number Publication Date
KR900004937A true KR900004937A (en) 1990-04-13

Family

ID=22933553

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890013596A KR900004937A (en) 1988-09-20 1989-09-20 RNA catalyst to segment unusual RNA sequence

Country Status (9)

Country Link
EP (3) EP0812912A1 (en)
JP (1) JP3167304B2 (en)
KR (1) KR900004937A (en)
AT (2) ATE160584T1 (en)
AU (3) AU641900B2 (en)
CA (1) CA1340323C (en)
DE (2) DE68928467T2 (en)
ES (2) ES2112006T3 (en)
GR (2) GR3022403T3 (en)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4091533T (en) * 1989-08-31 1992-01-30
GB9018646D0 (en) * 1990-08-24 1990-10-10 Imperial College Replication of a eukaryotic virus rna
DE4216134A1 (en) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog SYNTHETIC CATALYTIC OLIGONUCLEOTIDE STRUCTURES
AU656676B2 (en) * 1992-04-17 1995-02-09 Kirin Beer Kabushiki Kaisha Plant resistant to two or more viruses and preparation thereof
US6469158B1 (en) * 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5686599A (en) * 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) * 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
EP0653488B1 (en) * 1992-07-02 2003-04-09 Sankyo Company Limited Looped, hairpin ribozyme
US5891684A (en) * 1992-10-15 1999-04-06 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
US5422253A (en) * 1992-12-07 1995-06-06 Wisconsin Alumni Research Foundation Method of site specific nucleic acid cleavage
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
NZ267797A (en) * 1993-05-17 1997-09-22 Univ California Retroviral vector comprising a ribozyme capable of cleaving a hiv nucleic acid capable
WO1995004818A1 (en) * 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
ATE227342T1 (en) * 1993-09-02 2002-11-15 Ribozyme Pharm Inc ENZYMATIC NUCLEIC ACID CONTAINING NON-NUCLEOTIDES
DK0725788T3 (en) * 1993-10-27 1999-08-23 Ribozyme Pharm Inc 2'-amido and 2'-peptide modified oligonucleotides
CA2176035A1 (en) 1993-11-08 1995-05-18 Nassim Usman Base-modified enzymatic nucleic acid
US5631359A (en) * 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US5998193A (en) * 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US6350934B1 (en) 1994-09-02 2002-02-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid encoding delta-9 desaturase
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
US5672501A (en) * 1994-12-23 1997-09-30 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
US5705388A (en) * 1994-12-23 1998-01-06 Ribozyme Pharmaceuticals, Inc. CETP Ribozymes
US5663064A (en) * 1995-01-13 1997-09-02 University Of Vermont Ribozymes with RNA protein binding site
US5872241A (en) * 1995-01-25 1999-02-16 The Trustees Of Columbia University In The City Of New York Multiple component RNA catalysts and uses thereof
US5877021A (en) * 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
CN1196091A (en) * 1995-07-13 1998-10-14 里伯希姆药品公司 Compositions and method for modulation of gene expression in plants
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
EP0907746B1 (en) 1996-04-05 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6057156A (en) 1997-01-31 2000-05-02 Robozyme Pharmaceuticals, Inc. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
US6159951A (en) 1997-02-13 2000-12-12 Ribozyme Pharmaceuticals Inc. 2'-O-amino-containing nucleoside analogs and polynucleotides
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6183959B1 (en) 1997-07-03 2001-02-06 Ribozyme Pharmaceuticals, Inc. Method for target site selection and discovery
US6316612B1 (en) 1997-08-22 2001-11-13 Ribozyme Pharmaceuticals, Inc. Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
JP2001516582A (en) 1997-09-16 2001-10-02 クロップデザイン エヌ．ブイ． Cyclin-dependent kinase inhibitors and uses thereof
WO1999015641A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
JP4891477B2 (en) 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Methods for the regulation of angiogenesis and / or development of side arteries and / or other arteries from existing arteriole networks
US6054576A (en) * 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
WO1999025815A2 (en) 1997-11-18 1999-05-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nucleic acids involved in the responder phenotype and applications thereof
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2003525017A (en) 1998-04-20 2003-08-26 リボザイム・ファーマシューティカルズ・インコーポレーテッド Nucleic acid molecules with novel chemical composition that can regulate gene expression
CA2350398C (en) 1998-11-12 2010-08-10 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Chimeric promoters capable of mediating gene expression in plants upon pathogen infection and uses thereof
IL143266A0 (en) 1998-11-27 2002-04-21 Darwin Discovery Ltd Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
JP2002542805A (en) 1999-04-30 2002-12-17 ユニバーシティ オブ フロリダ Adeno-associated virus delivery ribozyme compositions and methods of use
WO2001005221A1 (en) 1999-07-20 2001-01-25 Ges. Für Erwerb Und Verwertung Von Schutzrechten-Gvs Mbh Novel method for the generation and selection of transgenic linseed/flax plants
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
ATE396265T1 (en) 2000-06-28 2008-06-15 Corixa Corp COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
EP1351707B9 (en) 2001-01-09 2012-01-25 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
DE60228477D1 (en) 2001-05-08 2008-10-02 Darwin Molecular Corp PROCESS FOR REGULATING THE IMMUNE FUNCTION IN PRIMATES USING THE FOXP3 PROTEIN
JP2005504513A (en) 2001-05-09 2005-02-17 コリクサ コーポレイション Compositions and methods for treatment and diagnosis of prostate cancer
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1572067A4 (en) 2001-05-18 2009-05-13 Sirna Therapeutics Inc Conjugates and compositions for cellular delivery
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8022272B2 (en) 2001-07-13 2011-09-20 Sungene Gmbh & Co. Kgaa Expression cassettes for transgenic expression of nucleic acids
US7456335B2 (en) 2001-09-03 2008-11-25 Basf Plant Science Gmbh Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
WO2003060143A2 (en) 2001-10-26 2003-07-24 Id Biomedical Corporation Of Washington Efficient protein expression system
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
DE10212892A1 (en) 2002-03-20 2003-10-09 Basf Plant Science Gmbh Constructs and methods for regulating gene expression
NZ573064A (en) 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
AU2003280420A1 (en) 2002-06-26 2004-01-19 Yale University Modulators and modulation of the interacton between rgm and neogenin
US7655790B2 (en) 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US6989442B2 (en) 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
NZ538284A (en) 2002-07-18 2008-04-30 Helix Biopharma Corp Use of urease and targeting molecule for inhibiting cancer cell growth
DE50310378D1 (en) 2002-07-26 2008-10-02 Basf Plant Science Gmbh NEW SELECTION PROCEDURES
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
EP2322535A3 (en) 2002-09-20 2011-09-28 Yale University Riboswitches, methods for their use, and compositions for use with riboswitches
CA2515699C (en) 2003-02-10 2015-01-27 Aya Jakobovits Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
EP1622572B1 (en) 2003-04-30 2017-12-20 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
SI1629088T1 (en) 2003-05-30 2012-08-31 Agensys Inc Prostate stem cell antigen (psca) variants and subsequences thereof
EP2267154A1 (en) 2003-10-23 2010-12-29 Illumigen Biosciences, Inc. Oligoadenylate synthetase
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
AU2005250370B2 (en) 2004-05-28 2010-04-01 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
WO2006013072A2 (en) 2004-08-02 2006-02-09 Basf Plant Science Gmbh Method for isolation of transcription termination sequences
EP1789552A2 (en) 2004-08-10 2007-05-30 Institute for Multiple Myeloma and Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
CA2579927A1 (en) 2004-09-24 2006-03-30 Basf Plant Science Gmbh Plant cells and plants with increased tolerance to environmental stress
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
JP4324636B2 (en) 2005-03-31 2009-09-02 アジェンシス，インコーポレイテッド Antibodies and related molecules that bind to 161P2F10B protein
WO2007039256A2 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
CA2628505A1 (en) 2005-11-08 2007-05-18 Basf Plant Science Gmbh Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants
US8313901B2 (en) 2005-12-21 2012-11-20 Yale University Methods and compositions related to the modulation of riboswitches
US8178751B2 (en) 2006-01-12 2012-05-15 Basf Plant Science Gmbh Use of stomatin (STM1) polynucleotides for achieving a pathogen resistance in plants
CA2644273A1 (en) 2006-04-05 2008-03-27 Metanomics Gmbh Process for the production of a fine chemical
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP2030021B1 (en) 2006-05-18 2012-11-21 Andreas Reichert Method for diagnosing mitochondrial dysfunction
US8592652B2 (en) 2007-01-15 2013-11-26 Basf Plant Science Gmbh Use of subtilisin-like RNR9 polynucleotide for achieving pathogen resistance in plants
EP2074219B1 (en) 2007-02-16 2013-11-20 BASF Plant Science GmbH Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
WO2008142036A2 (en) 2007-05-22 2008-11-27 Basf Plant Science Gmbh Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production-ko
EP2040075A1 (en) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Compounds and markers for surface-enhanced raman scattering
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
AU2008340002A1 (en) 2007-12-21 2009-07-02 Basf Plant Science Gmbh Plants with increased yield (KO NUE)
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
US9139554B2 (en) 2008-10-09 2015-09-22 Tekmira Pharmaceuticals Corporation Amino lipids and methods for the delivery of nucleic acids
EP2184351A1 (en) 2008-10-30 2010-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Polynucleotides encoding caryophyllene synthase and uses thereof
EP3238738B1 (en) 2008-11-10 2020-09-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
CA2751342C (en) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
DE112010003162T5 (en) 2009-04-22 2012-08-16 Basf Plant Science Company Gmbh Total seed-specific promoter
KR20220150411A (en) 2009-05-05 2022-11-10 알닐람 파마슈티칼스 인코포레이티드 Lipid compositions
EP2416652B1 (en) 2009-05-05 2018-11-07 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
SI3431076T1 (en) 2009-06-10 2022-04-29 Arbutus Biopharma Corporation Improved lipid formulation
CA2767127A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
CA2779073C (en) 2009-10-30 2017-10-24 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
EP3296398A1 (en) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
CN102656190A (en) 2009-12-08 2012-09-05 雅培股份有限两合公司 Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
LT2561067T (en) 2010-04-23 2019-03-12 University Of Florida Research Foundation, Inc. Raav-guanylate cyclase compositions and methods for treating leber`s congenital amaurosis-1 (lca1)
US8476485B2 (en) 2010-06-24 2013-07-02 Academia Sinica Non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012044992A2 (en) 2010-09-30 2012-04-05 Agency For Science, Technology And Research (A*Star) Methods and reagents for detection and treatment of esophageal metaplasia
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
WO2012109157A2 (en) 2011-02-07 2012-08-16 The Governing Council Of The University Of Toronto Bioprobes and methods of use thereof
US20140044644A1 (en) 2011-02-21 2014-02-13 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
MX2013013627A (en) 2011-06-21 2014-04-25 Oncofactor Corp Compositions and methods for the therapy and diagnosis of cancer.
US9701623B2 (en) 2011-09-27 2017-07-11 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
DK2817287T3 (en) 2012-02-24 2019-01-02 Arbutus Biopharma Corp TRIALKYL CATIONIC LIPID AND METHODS FOR USING IT
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2014127835A1 (en) 2013-02-22 2014-08-28 Christian-Albrechts-Universität Zu Kiel Plant-derived resistance gene
US10808246B2 (en) 2013-07-11 2020-10-20 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
CA3150458A1 (en) 2019-08-14 2021-02-18 Acuitas Therapeutics, Inc. Improved lipid nanoparticles for delivery of nucleic acids
IL307298A (en) 2021-03-31 2023-11-01 Entrada Therapeutics Inc Cyclic cell penetrating peptides
JP2024518068A (en) 2021-05-10 2024-04-24 エントラーダ セラピューティクス，インコーポレイティド Compositions and methods for intracellular therapy
WO2022240721A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
EP4337261A2 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions and methods for modulating mrna splicing
KR20240038967A (en) 2021-06-23 2024-03-26 엔트라다 테라퓨틱스, 인크. Antisense compounds and methods for targeting CUG repeats
CN117980315A (en) 2021-08-05 2024-05-03 美国圣因生物股份有限公司 1' -Alkyl modified ribose derivatives and methods of use
AU2022352676A1 (en) 2021-09-22 2024-03-14 Sanegene Bio Usa Inc. 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides
WO2023059695A1 (en) 2021-10-05 2023-04-13 Sanegene Bio Usa Inc. Polyhydroxylated cyclopentane derivatives and methods of use
WO2023144792A1 (en) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
WO2023144798A1 (en) 2022-01-31 2023-08-03 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
WO2023164464A1 (en) 2022-02-22 2023-08-31 Sanegene Bio Usa Inc. 5'-modified carbocyclic ribonucleotide derivatives and methods of use
WO2024015796A1 (en) 2022-07-11 2024-01-18 Sanegene Bio Usa Inc. Optimized 2'- modified ribose derivatives and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
WO1989005852A1 (en) * 1987-12-15 1989-06-29 Macphillamy Cummins & Gibson Ribozymes

Also Published As

Publication number Publication date
AU659330B2 (en) 1995-05-11
EP0812912A1 (en) 1997-12-17
DE68927456D1 (en) 1996-12-19
EP0700996A1 (en) 1996-03-13
GR3022403T3 (en) 1997-04-30
DE68928467T2 (en) 1998-03-19
AU4420793A (en) 1993-12-02
AU2850395A (en) 1996-03-28
DE68928467D1 (en) 1998-01-08
EP0360257A2 (en) 1990-03-28
CA1340323C (en) 1999-01-19
DE68927456T2 (en) 1997-03-20
ES2095210T3 (en) 1997-02-16
AU691007B2 (en) 1998-05-07
AU4159489A (en) 1990-03-29
ES2112006T3 (en) 1998-03-16
EP0700996B1 (en) 1997-11-26
EP0360257A3 (en) 1991-04-17
GR3026045T3 (en) 1998-05-29
JP3167304B2 (en) 2001-05-21
JPH03123485A (en) 1991-05-27
ATE145239T1 (en) 1996-11-15
EP0360257B1 (en) 1996-11-13
ATE160584T1 (en) 1997-12-15
AU641900B2 (en) 1993-10-07

Similar Documents

Publication Publication Date Title
KR900004937A (en) RNA catalyst to segment unusual RNA sequence
Thomson et al. Activity of hammerhead ribozymes containing nonnucleotidic linkers
Ohkawa et al. Importance of independence in ribozyme reactions: kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus.
ES2056799T3 (en) CODANT DNA MOLECULES FOR THE FMDH CONTROL AND STRUCTURAL GENE REGIONS FOR A PROTEIN THAT HAS AN FMDH ACTIVITY AND ITS USE.
DK0941318T3 (en) Dumbbell-shaped gene expression expression systems
KR830005350A (en) Method for producing fusion protein and eukaryotic protein for surface conjugate
ATE64151T1 (en) RECOMBINANT IMMUNOGLOBULIN PREPARATIONS, METHODS FOR THEIR PRODUCTION, DNA SEQUENCES, EXPRESSION VECTORS AND RECOMBINANT ACTIVE CELLS THEREOF.
KR950704497A (en) Protein Having Glycosyltransferase Activity
DK1056873T3 (en) Methods for producing a polypeptide in a Bacillus cell
NO951364L (en) DNA compounds comprising sequences encoding mannuronan C-5 epimerase
KR970701199A (en) Growth Arrest Homeobox Gene
KR910008132A (en) Multifunctional RNA having self processing activity, preparation method and use thereof
DE69834565D1 (en) FAST GENERATION OF STABLE MAMMALIAN ANIMAL CELL LINES WITH RECOVERY OF HIGH QUANTITY OF RECOMBINANT PROTEINS
DK1585822T3 (en) Promoter variants for expression of genes in a fungal cell
NZ502450A (en) Recombinant expression of multimeric polypeptide comprising multiple copies of insulin c-peptide
KR960700262A (en) SYNTHESIS OF DIMMER BLOCKS AND THEIR USE IN ASSEMBLING OLIGONUCLEOTIDES
Campbell An RNA replisome as the ancestor of the ribosome
WO1998049182A3 (en) Gggg or gtgt as carriers for drug delivery
Fauquet et al. Genetic engineering technologies to control viruses and their application to cassava viruses
DE3586145D1 (en) RECOMBINANT DNA, THESE MICROORGANISMS CONTAINING THEM AND THEIR USE FOR THE PRODUCTION OF AMYLASES.
KR970001543A (en) New promoter and gene expression method using the same
Langridge Precambrian evolutionary genetics
Roman Genetics of some microorganisms
Cowley et al. In vitro cleavage of bovine ephemeral fever virus mRNA species with synthetic hammerhead ribozymes.[Symposium paper]
BEERNER TUE NATIONAL ACADEMY O0F SCIENCES

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application